Crucell corporate brochure (PDF)

08
Overview
Message from our CEO
Crucell’s mission to bring meaningful
innovation to global health reflects a deep
commitment to improving the lives of people
worldwide. This underpins everything we do
as a global organization and as individuals
united by a common purpose.
1 Figure based on Crucell’s top five vaccines in terms of sales volumes: Quinvaxem®,
Hepavax-Gene®, Epaxal®, Vivotif® and Inflexal® V.
2 Figures based on Crucell’s top 5 vaccines Quinvaxem®, Hepavax-Gene®, Epaxal®, Vivotif®
and Inflexal® V. Total 101,666,000 doses minus 2% waste (2,033,320 doses) = 99,632,680
doses sold in 2010 / 525600 minutes in 2010 = 189.5598 doses administered per minute.
www.crucell.com
I am therefore delighted that talks held with Johnson & Johnson
during 2010 have resulted in Crucell becoming the center of excellence
for vaccines within the world’s largest and possibly most respected
healthcare company. As a member of the Johnson & Johnson Family
of Companies, we can do so much more to make the world we live in
a healthier place. The combination of our two companies will enable
Crucell to further accelerate growth, and our shared expertise and
talent will help to make an even bigger difference in the lives of people
worldwide. We are delighted by the prospect of pursuing our mission
with the support of Johnson & Johnson that shares our passion for
healthcare innovation, our values and our commitment to care for people.
Protecting and contributing to society in the fullest possible sense
and to the best of our ability is our core business, our passion
and the essence of our company. Our commitment to the principles
of corporate social responsibility is a logical extension of our mission
to bring innovation to global health, focusing especially on the
prevention of infectious diseases.
During 2010, we distributed over 105 million 1 doses of vaccines
to people around the world, with the majority going to infants in
developing countries. The range of vaccines we have on the market
prevents twelve major infectious diseases: childhood infections, travel
and endemic illnesses, and respiratory disease. We estimate that a
Crucell vaccine was given to 190 individuals 2 every minute during 2010,
a thought that makes us very proud.
However, I believe that the best measure of our impact on global health
is not the number of doses we supply, but the number of deaths and
cases of disease we prevent each year. In 2010, Crucell’s ‘top-five’
vaccines prevented more than 3.6 million cases of infectious disease
and 809,823 deaths. 1
Crucell’s core business is the discovery, development and delivery
of innovative solutions for major health threats. Our specialty is the
creation of much-needed immunization products: vaccines that safely